Most of the modulation indexes proposed in the literature are related to the robustness and modulation of a plan. However, none of them has been conceived to appropriately predict the interplay effect in lung SABR. MIt has been found to be the only published index capable of detecting failing plans. MIt and PUMA have the same specificity since both detected all of the failing plans. However, PUMA has a greater accuracy and sensitivity. Purpose or Objective: The objective of this HERO study was to assess the number of new cancer patients that will require at least one course of radiotherapy by 2025 compared to the 2012 figure, by tumor site and European country.
Material and Methods: European cancer incidence data by tumor site and country for 2012 and 2025 was extracted from the GLOBOCAN database. The projection of the number of new cases took into account demographic factors (age and size of the population). Population based stages at diagnosis were taken from four European countries. Incidence and stage data were introduced in the Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) model, thus producing an evidence-based proportion of incident cases with an indication for radiotherapy, the Optimal Utilization Proportion (OUP). From these values, the number of cases that would require radiotherapy on an annual basis in each country was calculated.
Results: Among the difference tumor sites, the highest expected relative increase by 2025 in treatment courses was prostate cancer (24%) while lymphoma (13%), head and neck (12%) and breast cancer (10%) were below the average. Cervical (1%) and testicular cancer (-6%) were the sites with the lowest expected increase. Based on the projected cancer distributions in 2025, a 16% expected increase in the number of radiotherapy treatment courses was estimated. This increase varied across European countries from less than 5% (Bulgaria, Latvia, Lithuania, Ukraine, Belarus, Estonia, Moldova) to more than 30% (Switzerland, Luxembourg, Malta, Iceland, Ireland, Albania, Cyprus) .
Conclusion:
This HERO study showed that the need for radiotherapy in Europe is, on average, expected to increase with 16% over the next decade. The expected changes varied considerably between countries (range 0-38%). With the already existing disparity in radiotherapy resources in mind, the data provided here should act as a leverage point to raise awareness among European health policy makers of the need for investment in radiotherapy. Purpose or Objective: Current clinical trials and studies are identifying hypofractionation as a viable treatment option when compared with current fractionation regimens. Our work estimates the reduction in the number of fractions prescribed and the potential effect on the overall demand for radiotherapy across the whole of England. With the evidence based estimates of demand for radiotherapy currently outstripping the supply capacity in England, this potential reduction in fraction demand needs to be calculated to assess the potential effects for radiotherapy service and infrastructure planning.
OC-0332

Material and Methods:
The Malthus Program, a tool for modelling radiotherapy demand, was used to calculate the potential effect of three hypofractionation studies/trials for the population of England. Well-published and potential clinical indications for hypofractionation have been modelled for prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer. The hypofractionation indications for radiotherapy were mapped into the original Malthus clinical decision trees and simulations completed to study the effects of hypofractionation on demand.
Results: If the CHHiP prostate trial achieves universal uptake throughout England then it has the potential to reduced radiotherapy demand by 3,500 fractions per million population (#pmp). SBRT for medically inoperable (or refusal of surgery) for stage 1 and stage 2 NSCLC has the potential to reduce the demand by a further 700 #pmp. The FAST-Forward trial, using 5# instead of 15# for T1-3 N0-1 M0 breast cancer S154 ESTRO 35 2016 _____________________________________________________________________________________________________ has the potential to reduce demand by 4,600 #pmp. A potential reduction in modelled demand of 8,800 #pmp arises from these three studies alone. Across the total population of England, this translates to approximately 479,600 fractions per year.
Conclusion:
The current clinical indications and trials for hypofractionation have the potential to reduce the evidencebased estimates of demand of radiotherapy sufficiently to be achievable with a modest increase of the current levels of equipment in England. While the presented calculations are for England as a whole, the Malthus program offers the facility to calculate the changes in modelled demand at a regional level within England, enabling a more precise calculation for treatment centres and their local catchment. For each cancer, the data set consisted of the incidence date, topography, histology, TNM stage and the treatment recommendations formulated during the multidisciplinary team meetings (MDT), the latter giving an indication on the pattern of radiotherapy prescription in Belgium. Data on reimbursement for external beam radiotherapy, obtained through linkage with the administrative database from the Health Insurance Companies and covering a time period up till 3 years after the year of incidence, provided insight in the actual utilization. Besides overall analyses at the Belgian population level, variability of actual and optimal utilization amongst cancer types was assessed. For the Belgian cancer population diagnosed in 2009-2010, the actual use of radiotherapy was 35.1%. About 3 in 4 of these patients received radiotherapy within the first 9 months after diagnosis, providing an estimate of those irradiated in the context of the primary treatment strategy. The global result was in line with the percentage of prescribed or recommended radiotherapy series (35.0%) during the MDT. Radiotherapy uptake varied with primary tumour site. Most of the cancers in Belgium have a lower actual utilization than predicted with the exception of leukaemia, ovarian, thyroid, testicular, colon and liver cancer. Most pronounced differences between optimal and actual utilization were found in less typical radiotherapy indications such as in bladder, brain, lymphoma, myeloma, pancreas and stomach cancer. For more common radiotherapy indications such as breast, head and neck and rectal cancer, the underutilization is about 10-15% while in lung, oesophagus and prostate cancer, the underuse was more pronounced resulting in only about 55-60% of the patients requiring radiotherapy being actually treated. These data, derived at the unique patient-level, illustrate that even in a country that is well-resourced in terms of radiotherapy staffing and infrastructure, a clear discrepancy can be observed between the optimal and actual radiotherapy delivery. Potential reasons for this may include physician and patient preferences favouring non-radiotherapy regimens in case of competing treatment modalities (e.g. in prostate cancer), deviation from guidelines (e.g. due to comorbidity or low performance status), an overestimation of the real needs by the evidence-based OUP-model and an underestimation of the actual utilisation due to available nomenclature data being limited to 3 years after incidence. These reasons all deserve further evaluation and they must be carefully taken into account when forecasting and planning radiotherapy staffing and infrastructure. (NCPs) or strategies by 2013. In the Joint Action (JA) EPAAC, which acted as the practical implementation of the partnership, the status of the national cancer plan development was revised through a comprehensive survey in all MSs, Norway and Iceland. What should be practical consequences of an NCP? In principle they should be the following: Mapping all the processes belonging to the comprehensive control and management of cancerIdentifying priorities in cancer careDefining clear patient pathways and assuring the necessary resources for themSecuring sufficient financial resources through the implementation of both guidelines and patient pathwaysIntroducing new programmes -therapeutic and screening, treatment approaches and new concepts, such as survivorship.Raising awareness of the different elements in
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